Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Exploring the Gig Economy: Illustrations from Consultants - 2Discovering a sense of harmony: Individual Accounts of Reflection and Care
- 3Protester climbs on to balcony of Iranian embassy in London
- 4Artemis 2 astronauts see Earth in the rear-view mirror | Space photo of the day for April 3, 2026
- 5Thermo Fisher wins contracts as pharma shifts production to US, CEO says
- Explosions at Burundi ammunition depot kill civilians, witnesses say
- ByHeart baby formula from all lots may be contaminated with botulism bacteria, tests show
- This cafe takes orders in sign language. It's cherished by the Deaf community
- Video Conferencing Instruments for Virtual Gatherings
- Do-It-Yourself Home Style on a Careful spending plan: Imaginative Thoughts and Tasks
- German journalists' union condemns attack on reporters in village
- One killed, several injured in Iran missile barrage on southern, central Israel
- Netflix Faces Wider Fallout After Italy Court Orders Refunds, Price Cuts
- EU states agree first step for Ukraine reparations fund
